Čájehuvvojit 1 - 2 oktiibuot 2 bohtosis ohcui on behalf of the FUTURE 2 Study Group', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

    Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study Dahkki Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group

    Almmustuhtton 2018-06-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

    Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... Dahkki L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group

    Almmustuhtton 2018-12-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: